Biomarin's previously rejected hemophilia drug gets special status at the FDA

The FDA in the US has given Biomarin's gene therapy against hemophilia special status, which will speed up the approval process. The treatment was rejected in August last year.

Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix

When Biomarin again tries to get the US Food and Drug Administration (FDA) to approve the hemophilia treatment valoctocogene roxaparvovec, it'll get some help along the way.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs